Sustained release pharmaceutical compositions in oral dosage form
October 4, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesControlled release tablet Hexahydronaphth[1,2-b]-1,4-oxazines Retard form of pharmaceuticals with insoluble porous diffusion coatings Controlled release formulation and method Method for preparing a pharmaceutical controlled release composition Controlled release formulation Naphthoxazines and their use as psychostimulating and antidepressant agents Ethylcellulose-coated, gastric-disintegrable aspirin tablet Controlled release dosage forms comprising hydroxypropylmethylcellulose Controlled absorption methyldopa pharmaceutical formulation Patent #: 4716040 InventorsAssigneeApplicationNo. 418821 filed on 10/04/1989US Classes:424/480, Cellulose or derivative424/473, With porous, perforated, apertured, or sieved layer (e.g., dialyzing layer, microporous layer, etc.)424/482, Containing solid synthetic polymers424/494, Cellulose derivatives424/495, Ethyl cellulose424/497Containing solid synthetic polymersExaminersPrimary: Dixon, William R. Jr.Assistant: Johnson, Jerry D. Attorney, Agent or FirmInternational ClassesA61K 009/36A61K 009/16 Foreign Application Priority Data1986-07-09 GBAbstractOral dosage forms for neutral, zwitterions or slats of acidic or basic drugs with approximate zero order release kinetics comprise a core matrix of the drug, and a gelling polymer, the matrix being coated with a water permeable but insoluble polymer. | |
